Growth Hormone Resistance of Beta-cells in Women and People

Launched by UNIVERSITY OF MISSOURI-COLUMBIA · Aug 22, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring how beta-cells in the pancreas, which are responsible for making insulin and controlling blood sugar, respond to growth hormone in people who have a family history of type 2 diabetes. The researchers at the University of Missouri want to learn more about how growth hormone impacts these cells, especially in relation to the risk of developing gestational diabetes and type 2 diabetes.

To participate in this study, individuals must be between 18 to 45 years old, have a body mass index (BMI) of 30 to 45 (indicating obesity), and should have normal blood sugar levels. Participants may either have a first-degree relative with type 2 diabetes or be part of a control group with no family history of the disease. If you join the study, you can expect to undergo assessments related to your health and the effects of growth hormone on your beta-cells. It’s important to note that pregnant women, those with diabetes, and individuals with certain health conditions or who are on specific medications cannot participate. This research aims to contribute valuable insights into diabetes risk factors and how our bodies respond to hormones.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 to 45 years old
• • hemoglobin HbA1c ≤5.6% and fasting blood glucose \<100 mg/dl
• • body mass index ≥30.0 kg/m2 and \<45.0 kg/m2
• Additional, group-specific inclusion criteria:
• • Family history of type 2 diabetes: first degree relative with type 2 diabetes
• • Control group: no family history of type 2 diabetes
• Exclusion Criteria:
• • Pregnant, planning to become pregnant during the study, or breastfeeding
• • Current diagnosis or history of type 1 or type 2 diabetes
• • Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)
• • History of bariatric surgery
• • Known hypothyroidism or use of thyroid medications
• • History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment
• • Current cancer or cancer that has been in remission less than 5 years
• • First degree relative with type 1 diabetes diagnosis
• • Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)
• • Alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day
• • Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration
• • Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent